Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Astha-15 (DCBT4567-Astha-15) is a polyherbal formulation developed for the management of reversible bronchial asthma. It is derived from a combination of medicinal plants traditionally used in Ayurvedic medicine, including extracts from *Adhatoda vasica*, *Glycyrrhiza glabra*, and *Solanum xanthocarpum*. In clinical trials, Astha-15 has demonstrated efficacy in improving lung function, specifically increasing forced expiratory volume in 1 second (FEV1), and significantly reducing clinical symptoms such as dyspnoea, wheezing, cough, and expectoration. Its performance has been shown to be comparable to conventional bronchodilators like salbutamol, while also enhancing the overall quality of life for patients with asthma.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Astha-15.